ACADS Antibody (B-8): sc-365648

ACADS Antibody (B-8) is a mouse monoclonal IgG2a antibody that detects ACADS (acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain) in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). ACADS is a crucial mitochondrial flavoprotein composed of 412 amino acids and functions as a homotetramer, playing a vital role in the mitochondrial fatty acid beta-oxidation pathway by catalyzing the rate-limiting step. This process is essential for the breakdown of fatty acids, which provides energy for cellular functions, particularly during periods of fasting or prolonged exercise. Deficiencies in ACADS can lead to serious metabolic disorders, such as short-chain acyl-CoA dehydrogenase deficiency, characterized by the accumulation of butyrylcarnitine and ethylmalonic acid, resulting in acute acidosis and muscle weakness in infants, as well as lipid-storage myopathy in adults. The presence of four FAD domains within the ACADS structure is significant, as these domains are critical for the enzyme′s activity and stability, underscoring the importance of this protein in maintaining metabolic homeostasis. Anti-ACADS antibody (B-8) is an invaluable tool for researchers studying fatty acid metabolism and related disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ACADS Antibody (B-8) References:

1. The ACADS gene variation spectrum in 114 patients with short-chain acyl-CoA dehydrogenase (SCAD) deficiency is dominated by missense variations leading to protein misfolding at the cellular level.  |  Pedersen, CB., et al. 2008. Hum Genet. 124: 43-56. PMID: 18523805
2. Mutations of ACADS gene associated with short-chain acyl-coenzyme A dehydrogenase deficiency.  |  Kim, SH., et al. 2011. Ann Clin Lab Sci. 41: 84-8. PMID: 21325261
3. Reveal genes functionally associated with ACADS by a network study.  |  Chen, Y. and Su, Z. 2015. Gene. 569: 294-302. PMID: 26045367
4. Dynamic modelling of an ACADS genotype in fatty acid oxidation - Application of cellular models for the analysis of common genetic variants.  |  Matejka, K., et al. 2019. PLoS One. 14: e0216110. PMID: 31120904
5. ACADS acts as a potential methylation biomarker associated with the proliferation and metastasis of hepatocellular carcinomas.  |  Chen, D., et al. 2019. Aging (Albany NY). 11: 8825-8844. PMID: 31652420
6. Effects of genetic variations in Acads gene on the risk of chronic obstructive pulmonary disease.  |  Yuan, Y., et al. 2020. IUBMB Life. 72: 1986-1996. PMID: 32593204
7. Analysis of genotypes and biochemical phenotypes of neonates with abnormal metabolism of butyrylcarnitine.  |  Wu, D., et al. 2023. Zhejiang Da Xue Xue Bao Yi Xue Ban. 52: 707-713. PMID: 38105686
8. Combined Multi-Omics Analysis Reveals the Potential Role of ACADS in Yak Intramuscular Fat Deposition.  |  Xu, F., et al. 2024. Int J Mol Sci. 25: PMID: 39201818
9. DNA methylation of ACADS promotes immunogenic cell death in hepatocellular carcinoma.  |  Qian, Z., et al. 2025. Cell Biosci. 15: 3. PMID: 39800718
10. Amino acid polymorphism (Gly209Ser) in the ACADS gene.  |  Kristensen, MJ., et al. 1994. Hum Mol Genet. 3: 1711. PMID: 7833941

The preferred ACADS antibody is ACADS Antibody (G-10): sc-365953.